Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)

Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP): a Prospective Observational Study

Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.

Study Overview

• Status: Recruiting
• Conditions: Aging; Hip Fractures; Osteoporosis; Osteoarthritis, Hip; Clonal Hematopoiesis of Indeterminate Potential
• Intervention / Treatment: Other: Blood and bone marrow cell collection

• Study Type: Observational
• Enrollment (Estimated): 24

Contacts and Locations

• Study Contact: Name: Michaël R. Laurent, MD PhD; Phone Number: +32485143267; Email: michael.laurent@imelda.be

Study Locations

• Belgium
  • België
    • Bonheiden, België, Belgium, 2820
      • Recruiting
      • Imelda Hospital
      • Contact: Michaël R. Laurent, MD PhD; Phone Number: +32485143267; Email: michael.laurent@imelda.be
      • Sub-Investigator: Hans Casteur, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing hip arthroplasty for hip osteoarthritis or osteoporotic hip fractures.

Description

Inclusion Criteria:

• Age 65 years and older

Exclusion Criteria:

• known haematological condition (myelodysplasia, leukemia, cancer)
• inability to provide written informed consent

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Osteoporotic hip fracture patients	Other: Blood and bone marrow cell collection; Collection of blood and bone marrow
Hip osteoarthritis patients	Other: Blood and bone marrow cell collection; Collection of blood and bone marrow

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Gene Set Enrichment Analysis (GSEA) Normalized Enrichment Score (NES)	One day

Collaborators and Investigators

• Sponsor: Imelda Hospital, Bonheiden
• Collaborators: Université Catholique de Louvain
• Investigators: Principal Investigator: Nick Van Gastel, PhD, de Duve Institute

Study record dates

Study Major Dates

• Study Start (Actual): February 11, 2022
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: February 10, 2022
• First Submitted That Met QC Criteria: February 10, 2022
• First Posted (Actual): February 18, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2026
• Last Update Submitted That Met QC Criteria: March 24, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Wounds and Injuries; Arthritis; Joint Diseases; Rheumatic Diseases; Metabolic Diseases; Leg Injuries; Fractures, Bone; Bone Diseases, Metabolic; Osteoarthritis; Femoral Fractures; Hip Injuries; Nutritional and Metabolic Diseases; Osteoporosis; Hip Fractures; Osteoarthritis, Hip; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Blood Specimen Collection
• Other Study ID Numbers: 20211214

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No